EUCTR2015-003812-19-GB进行中（未招募）1 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF ONCE DAILY ORAL ZPL-3893787-18 (30 MG) ADMINISTERED FOR 12 WEEKS IN ADULT SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS. - A Phase 2a study of oral ZPL-3893787 in adults with plaque psoriasis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 129
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study
- •1. A documented history of moderate to severe plaque psoriasis for at least 6 months prior to screening.
- •2. Male or female, aged =18 years.
- •3. Females should be either of non-child-bearing potential or must agree to use highly effective methods of contraception. Males with partners who are WOCBP must also use contraception.
- •4. Body weight of = 50 kg.
- •5. Body Mass Index of =34.9 kg/m2.
- •6. Psoriasis Area and Severity Index (PASI) =10 at both Screening and Day 0.
- •7. An Investigator’s Global Assessment (IGA) score = 3 at both Screening and Day 0.
- •8. Psoriasis affecting =10% BSA at Screening and Day 0.
- •9. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, diary completion and other study procedures.
- •10. Willing to avoid exposure to sun, UVA or UVB from screening until completion of the follow up visit.
- •11. Evidence of a personally signed and dated informed consent form, indicating that the subject has been informed of all pertinent aspects of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Subjects presenting with any of the following will not be included in the study:
- •1. Concurrent skin disease (e.g. acne) of such severity in the study area that it could interfere with the study evaluation or presence of skin comorbidities that may interfere with study assessments.
- •2. Biologic treatments for psoriasis (e.g. Enbrel, Humira, Stelara, Cosentyx) within 3 months of the start of the Run-In.
- •3. Phototherapy (e.g. UVA, UVB, PUVA) within 4 weeks of the start of the Run-In.
- •4. Oral calcineurin inhibitors and immunosuppressants (e.g. cyclosporine, azathioprine, methotrexate) within 4 weeks of the start of the Run-In.
- •5. Systemic corticosteroids within 4 weeks of the start of the Run-In.
- •6. Oral antihistamines and leukotriene inhibitors and tricyclic antidepressants within 1 week of the start of the Run-In.
- •7. Topical steroids (any potency), topical calcineurin inhibitors (tacrolimus, pimecrolimus), salicylic acid and urea containing treatments and coaltar preparations, topical and oral retinoids and vitamin D derivatives, within 1 week of the start of the Run-In.
- •8. Subjects who are using any concomitant medication(s) that in the investigators’ opinion could affect psoriasis (e.g. ß-blockers, lithium) within the 3 months prior to the start of the Run-In.
- •9. Potent CYP1A inhibitors (e.g. ciprofloxacin, enoxacin, fluvoxamine) from the start of the Run-In.
- •10. Evidence of significant concomitant clinical disease that may need a change in management during the study or could interfere with the conduct or safety of this study (Stable well-controlled chronic conditions such as controlled hypertension (BP<140/90 mmHg) thyroid disease, well-controlled Type 1 or Type 2 diabetes (HbA1c< 8%), hypercholesterolemia, gastroesophageal reflux, or depression under control with medication (other than tricyclic antidepressants), are acceptable provided the symptoms and medications would not be predicted to compromise safety or interfere with the tests and interpretations of this study).
- •11. Clinically significant cardiac disease or ECG abnormalities, including:
- •Predominant heart rhythm other than normal sinus rhythm
- •AV block greater than first degree
- •Resting heart rate >100 or <50 bpm
- •Electrocardiographic evidence or a history of myocardial infarction
- •Electrocardiographic evidence of conduction system abnormality
- •Subjects with pre-randomization evidence of QTcF prolongation (defined as >450 msec)
研究者
相似试验
进行中（未招募）
不适用
A study to determine the effects of 8 week treatment with an oral drug called ZPL-3893787 in adult subjects with moderate to severe atopic dermatitis.Atopic Dermatitis (AD)MedDRA version: 18.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2014-005057-39-PLZiarco Pharma Ltd90
已完成
不适用
CLINICAL STUDY TO EVALUATE IMMUNITY MODULATING EFFECTS ON HEALTHY SUBJECTSCTRI/2020/09/027961Tenshi Kaizen Pvt Ltd India60
进行中（未招募）
1 期
A study to determine the effects of 8 week treatment with an oral drug called ZPL-3893787 in adult subjects with moderate to severe atopic dermatitis.EUCTR2014-005057-39-BEZiarco Pharma Ltd90
进行中（未招募）
不适用
A clinical trial of MABT5102A for the treatment of Alzheimer's DiseaseMedDRA version: 14.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's DiseaseEUCTR2010-021926-37-DEGenentech Inc450
进行中（未招募）
1 期
A study to determine the effects of 8 week treatment with an oral drug called ZPL-3893787 in adult subjects with moderate to severe atopic dermatitis.Atopic Dermatitis (AD)MedDRA version: 18.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858EUCTR2014-005057-39-GBZiarco Pharma Ltd98